Martin Capital Advisors LLP Has $2.29 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Martin Capital Advisors LLP increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 4,117 shares of the company’s stock after acquiring an additional 23 shares during the period. IDEXX Laboratories comprises 1.9% of Martin Capital Advisors LLP’s investment portfolio, making the stock its 14th biggest position. Martin Capital Advisors LLP’s holdings in IDEXX Laboratories were worth $2,285,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC lifted its stake in IDEXX Laboratories by 121,647.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after buying an additional 7,441,162 shares during the period. Norges Bank acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth $336,416,000. International Assets Investment Management LLC raised its stake in IDEXX Laboratories by 51,631.3% during the fourth quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock worth $304,075,000 after buying an additional 546,775 shares during the last quarter. Morgan Stanley lifted its holdings in IDEXX Laboratories by 36.0% in the fourth quarter. Morgan Stanley now owns 986,232 shares of the company’s stock valued at $402,344,000 after buying an additional 260,926 shares during the period. Finally, Alliancebernstein L.P. boosted its position in IDEXX Laboratories by 6.4% during the second quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock valued at $1,804,428,000 after acquiring an additional 214,529 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of recent analyst reports. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. JPMorgan Chase & Co. increased their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Barclays lifted their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a research note on Tuesday, January 30th. Finally, The Goldman Sachs Group lifted their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $591.50.

IDEXX Laboratories Stock Down 0.3 %

Shares of IDEXX Laboratories stock traded down $1.44 during trading hours on Friday, reaching $476.35. The company’s stock had a trading volume of 565,634 shares, compared to its average volume of 429,180. The company has a market capitalization of $39.56 billion, a P/E ratio of 47.45, a P/E/G ratio of 3.68 and a beta of 1.26. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The stock’s fifty day simple moving average is $539.94 and its two-hundred day simple moving average is $508.49.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. During the same quarter in the prior year, the business posted $2.05 EPS. The business’s revenue was up 8.8% compared to the same quarter last year. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now directly owns 29,718 shares in the company, valued at $16,939,557.18. The disclosure for this sale can be found here. Insiders sold a total of 43,524 shares of company stock valued at $24,871,960 in the last three months. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.